NCT01463059已完成2 期
A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 119
- 试验地点
- 39
- 主要终点
- Change from Baseline in the Disease Activity Score 28-joint count (C-reactive protein) (DAS28[CRP]) at Week 12
研究概览
简要总结
The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA
- •Must have moderately to severely active RA disease as defined by ≥6 tender joints (68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR >28mm/hour
- •Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable route of administration
- •Must have had intolerance or inadequate response to treatment with 1 or more TNF-blocker therapies within 2 years of Screening
- •Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception
排除标准
- •Have a diagnosis of any other inflammatory arthritis
- •Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks
- •Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)
- •Subjects with known concurrent acute or chronic viral hepatitis B or C infection
- •Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB infection
- •Subjects with known history of or current clinically active infection
- •Subjects at high risk of infection
- •Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic virus type 1 (HTLV 1) infection
- •Have received vaccinations within 8 weeks prior to Screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted)
- •Concurrent malignancy or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to Screening
结局指标
主要结局
Change from Baseline in the Disease Activity Score 28-joint count (C-reactive protein) (DAS28[CRP]) at Week 12
时间窗: From Week 0 (Baseline) to Week 12
次要结局
- Number of responders in American College of Rheumatology 20% Response Criteria (ACR20) at Week 12(From Week 0 (Baseline) to Week 12)
- Number of responders in American College of Rheumatology 50% Response Criteria (ACR50) at Week 12(From Week 0 (Baseline) to Week 12)
- Number of responders in American College of Rheumatology 70% Response Criteria (ACR70) at Week 12(From Week 0 (Baseline) to Week 12)
研究者
研究点 (39)
Loading locations...
相似试验
已完成
1 期
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using MethotrexateArthritisRheumatoid ArthritisNCT01009242UCB Pharma40
已完成
1 期
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy MalesPharmacokineticsNCT01276119UCB Pharma67
已完成
2 期
Three Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00097331GlaxoSmithKline261
已完成
2 期
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With MenopauseHot FlashesNCT00314964Pfizer527
已完成
2 期
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's DiseaseCrohn's DiseaseNCT00101946GlaxoSmithKline17